



April 27, 2023

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi - 74000

GlaxoSmithKline
Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi – 74000,
Pakistan

T +92 21 111 475 725

Subject: **Financial Results for the three months ended March 31, 2023**
GlaxoSmithKline Pakistan Limited

Dear Sir,

This is to inform you that the Board of Directors of our Company in their meeting held on Thursday, April 27, 2023, at 11:00 a.m. in GSK Pakistan Limited, Sykes Building, 35 – Dockyard Road, West Wharf, Karachi, recommended the following:

(i) CASH DIVIDEND

NIL

The financial results of the Company are as follows:


	March 31, 2023	March 31, 2022
	<u>----- Rupees in '000 -----</u>	
Revenue from contracts with customers – net	11,399,120	8,625,964
Cost of sales	<u>(10,286,273)</u>	<u>(6,388,456)</u>
Gross profit	1,112,847	2,237,508
Selling, marketing and distribution expenses	(1,061,572)	(696,750)
Administrative expenses	(438,816)	(391,983)
Other operating expenses	(59,151)	(120,561)
Other Income	1,798,279	474,037
Operating profit	1,351,587	1,502,251



Financial charges	<u>(688,345)</u>	<u>(115,789)</u>
Profit before taxation	663,242	1,386,462
Taxation – net	<u>(232,680)</u>	<u>(461,421)</u>
Profit after taxation	430,562	925,041
Earnings per share – Rs.	<u>1.35</u>	<u>2.90</u>

The financial statements for the quarter ended March 31, 2023 of the Company will be transmitted through PUCARS in stipulated time.

Yours Sincerely,


Mehar-e-Daraksha Ameer
Company Secretary

cc: Head of Operation,
Central Depository Company of Pakistan Limited,
99-B, Block – B, S.M.C.H.S.,
Main Shakra-e-Faisal,
Karachi – 74000

Director/HOD,
Surveillance, Supervision and Enforcement Department
Securities and Exchange Commission of Pakistan
NIC Building, 63 Jinnah Avenue,
Blue Area,
Islamabad

31